Kymera Investor Presentation Deck

0 KT-253: Initial Clinical Activity Demonstrated in Phase 1a 23 21 42 Lesion 1 Pre-Treatment Lesion 2 Pre-Treatment 63 KYMERA ©2023 KYMERA THERAPEUTICS, INC. Days on Study - Dose Level 1 (0.05 mg/kg) 84 107 * 105 Post-Cycle 2 Post-Cycle 2 133 126 Merkel Cell Carcinoma Fibromyxoid Sarcoma Uveal Melanoma 147 Ongoing Discontinued (Progressive Disease) Partial Response Stable Disease *Patient discontinued from study 64-year-old male, diagnosed with Merkel cell carcinoma (rare and aggressive skin cancer) in 2019 Received 6 prior regimens including treatment with pembrolizumab, atezolizumab, nivolumab and ipilimumab Confirmed partial response after 4 cycles of KT-253, including resolution of skin metastasis; treatment continuing PAGE 37

View entire presentation